Employees: 03 (2023.0)Legal category: 5485Size: PMECreation date: 2015-08-01 (10 years)Status: ActiveBusiness sector: Commerce de détail de produits pharmaceutiques en magasin spécialiséLocation: COURBEVOIE (92400), Hauts-de-Seine
Les données financières de cette entreprise sont partiellement disponibles (liasse simplifiée ou données confidentielles). Certaines sections ne sont pas affichées.
SELARL PHARMACIE GUILLAIN : revenue, balance sheet and financial ratios
SELARL PHARMACIE GUILLAIN is a French company
founded 10 years ago,
specialized in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé.
Based in COURBEVOIE (92400),
this company of category PME
shows in 2025 a net income positive of 111 k€.
Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.
Financial history - SELARL PHARMACIE GUILLAIN (SIREN 812429017)
Indicator
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
Revenue
N/C
N/C
N/C
N/C
N/C
N/C
N/C
N/C
N/C
N/C
Net income
110 760 €
96 367 €
92 445 €
225 454 €
112 422 €
85 989 €
83 308 €
62 250 €
60 501 €
22 180 €
EBITDA
N/C
N/C
N/C
N/C
N/C
N/C
N/C
N/C
N/C
N/C
Net margin
N/C
N/C
N/C
N/C
N/C
N/C
N/C
N/C
N/C
N/C
Revenue and income statement
In 2025, SELARL PHARMACIE GUILLAIN generates positive net income of 111 k€. Net income represents the final profit after all expenses (operating, financial, exceptional) and corporate tax. Change over 2016-2025: 22 k€ -> 111 k€.
Net income (2025)
?
Net income
Definition
Profit or loss after all expenses, including taxes and exceptional items.
Formula
Current income + Exceptional income - Income tax
110 760 €
Loading income statement...
Income statement
Item
Amount
% Revenue
Change
The detailed income statement is not available for this company (simplified accounts or confidential data).
Chart evolution
Show :
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Assets
Loading data...
Item
Gross
Deprec.
Net
%
Change
Assets balance sheet data not available for this company
Liabilities
Loading data...
Item
Year
%
Change
Liabilities balance sheet data not available for this company
Solvency and debt ratios
The debt ratio (= Financial debt / Equity x 100) stands at 13%. This very low level reflects a solid financial structure, offering significant room for future investments or acquisitions. Financial autonomy (= Equity / Total assets x 100) reaches 77%. This high autonomy means the company finances most of its assets through equity, a sign of strength.
Debt ratio (2025)
?
Debt ratio
Definition
Measures the proportion of debt to equity.
Formula
(Financial debt / Equity) x 100
Interpretation
< 50% : Low 50-100% : Moderate > 100% : High
12.776%
Financial autonomy (2025)
?
Financial autonomy
Definition
Share of equity in the company's total financing.
Formula
(Equity / Total assets) x 100
Interpretation
> 30% : Good autonomy 20-30% : Average < 20% : Low
76.971%
Asset age ratio (2025)
?
Asset age ratio
Definition
Measures the degree of wear of tangible assets.
Formula
Accumulated depreciation / Gross fixed assets x 100
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Indicator
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Debt ratio
180.007
146.872
120.381
93.961
76.397
56.862
34.151
26.867
20.654
12.776
Financial autonomy
30.382
34.629
38.602
44.346
49.711
53.569
63.43
68.149
71.137
76.971
Repayment capacity
None
None
None
None
None
None
None
None
None
None
Cash flow / Revenue
None%
None%
None%
None%
None%
None%
None%
None%
None%
None%
Sector positioning
Debt ratio
12.782025
2023
2024
2025
Q1: 13.71
Med: 49.76
Q3: 129.07
Excellent
In 2025, the debt ratio of SELARL PHARMACIE GUILLAIN (12.78) ranks in the bottom 25% of the sector, which is positive. This ratio measures the weight of debt relative to equity. A low ratio indicates a solid financial structure with little dependence on creditors.
Financial autonomy
76.97%2025
2023
2024
2025
Q1: 33.42%
Med: 53.71%
Q3: 72.08%
Excellent
In 2025, the financial autonomy of SELARL PHARMACIE GUILLAIN (77.0%) ranks in the top 25% of the sector. This ratio represents the share of equity in total financing. High autonomy reflects financial independence and ability to absorb shocks.
Liquidity ratios
The liquidity ratio (= Current assets / Current liabilities) stands at 113.36. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months.
Liquidity ratio (2025)
?
Liquidity ratio
Definition
Ability to meet short-term debts with current assets.
Formula
Current assets / Current liabilities
Interpretation
> 1.5 : Very good 1-1.5 : Fair < 1 : Liquidity risk
Visualisation créée via abddaf.fr Sources : INPI & BCE - Retraitements : Ministère de l'économie
Indicator
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Liquidity ratio
302.691
68.228
70.346
64.521
70.731
96.255
119.404
116.647
117.258
113.364
Interest coverage
None
None
None
None
None
None
None
None
None
None
Sector positioning
Liquidity ratio
113.362025
2023
2024
2025
Q1: 131.03
Med: 182.29
Q3: 258.7
Watch
In 2025, the liquidity ratio of SELARL PHARMACIE GUILLAIN (113.36) ranks in the bottom 25% of the sector. This ratio measures the ability to cover short-term debt with current assets. A ratio below 1 may signal potential cash flow tensions.
Positioning of SELARL PHARMACIE GUILLAIN in its sector
Comparison with sector Commerce de détail de produits pharmaceutiques en magasin spécialisé
Valuation estimate
Based on 277 transactions of similar company sales
in 2025,
the value of SELARL PHARMACIE GUILLAIN is estimated at
1 759 435 €
(range 1 193 961€ - 2 760 797€).
This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.
Estimated enterprise value2025
277 transactions
1193k€1759k€2760k€
1 759 435 €Range: 1 193 961€ - 2 760 797€
NAF 5 année 2025
Valuation method used
Net Income Multiple
110 760 €
×
15.9x
=1 759 436 €
Range: 1 193 961€ - 2 760 797€
Only this financial indicator is available for this company.
Valuation evolution
Visualisation creee via abddaf.fr Sources : BODACC & INPI
How is this estimate calculated?
This estimate is based on the analysis of 277 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.
EBITDA Multiple: Preferred method for profitable SMEs. EBITDA reflects the ability to generate cash.
Revenue Multiple: Used for growing companies or those with low profitability. Reflects commercial potential.
Net Income Multiple: Relevant for mature companies with stable results.
This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).
Similar companies (Commerce de détail de produits pharmaceutiques en magasin spécialisé)
Compare SELARL PHARMACIE GUILLAIN with other companies in the same sector:
Frequently asked questions about SELARL PHARMACIE GUILLAIN
What is the revenue of SELARL PHARMACIE GUILLAIN ?
The revenue of SELARL PHARMACIE GUILLAIN is not publicly disclosed (confidential accounts filed with INPI).
Is SELARL PHARMACIE GUILLAIN profitable?
Yes, SELARL PHARMACIE GUILLAIN generated a net profit of 111 k€ in 2025.
Where is the headquarters of SELARL PHARMACIE GUILLAIN ?
The headquarters of SELARL PHARMACIE GUILLAIN is located in COURBEVOIE (92400), in the department Hauts-de-Seine.
Where to find the tax return of SELARL PHARMACIE GUILLAIN ?
The tax return of SELARL PHARMACIE GUILLAIN is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).
In which sector does SELARL PHARMACIE GUILLAIN operate?
SELARL PHARMACIE GUILLAIN operates in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé (NAF code 47.73Z). See the 'Sector positioning' section above to compare the company with its competitors.
Item evolution
Rotate your phone to landscape mode to view the chart